Concurrent use of Direct Acting Anticoagulants (DOACs) and antiplatelet medications appears to be common and confers a significantly increased risk of bleeding, an Australian study shows. Clinicians in Victoria have called for deprescribing of antiplatelets in patients taking DOACs after they found a five-fold higher risk of major bleeding events in patients taking both classes ...
Bleeding risk highlights need to deprescribe antiplatelets in patients taking DOACs
By Michael Woodhead
17 Nov 2020